잠시만 기다려 주세요. 로딩중입니다.

Overview of anti-Hepatitis B virus agents

Journal of Bacteriology and Virology 2020년 50권 3호 p.141 ~ 149
이혜원, 박용광, 최용욱,
소속 상세정보
이혜원 ( Lee Hye-Won ) - Korea National Institute of Health Center for Infectious Disease Research Division of Viral Disease Research
박용광 ( Park Yong-Kwang ) - Korea National Institute of Health Center for Infectious Disease Research Division of Viral Disease Research
최용욱 ( Choi Yong-Wook ) - Korea National Institute of Health Center for Infectious Disease Research Division of Viral Disease Research

Abstract


Since the first FDA approval of Lamivudine in 1998, many nucleo(t)side analogs such as Lamivudine, Adefovir, and Entecavir have been used. However, they only inhibit DNA synthesis, and if their administration is stopped a viral breakthrough can develop, making long-term administration necessary, ultimately followed by the development of resistance. Tenofovir has been developed and drug-resistant mutations have decreased significantly, but the problem of resistance due to long-term drug use still remains, along with the drug safety problem. In this review, we introduce the recent trend in the development of hepatitis B treatment agents and the Korea National Research Institute of Health (KNIH) research for the development of a novel treatment for hepatitis B (drug repositioning) without resistance and which targets the various life cycles of HBV.

키워드

Hepatitis B virus; anti-HBV agents; Drug resistance

원문 및 링크아웃 정보

 

등재저널 정보